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INTRODUCTION
In the treatment of diabetes, strict glycemic
plasma glucose control increases the incidence of
hypoglycemia, and fat accumulation-related obe-
sity frequently occurs according to DCCT (1) and
UKPDS 33 (2). The respiratory quotient (RQ) is a
noninvasive and simple test for evaluating both
glucose and fat metabolism and can provide differ-
ent information from serum levels of glucose and
hemoglobin A1c. The measurement of RQ facili-
tates the combustion of glucose and lipid meta-
bolic states as well as synthesis of fat from glu-
cose. When lipids are synthesized from surplus
glucose, the RQ increases to 1.0 or more (3).
With respect to the relationship between RQ and
diabetes, it has been reported that a reduced glu-
cose utilization decreased the RQ in untreated dia-
betics (4). However, our knowledge of the influence
of treatment on RQ is incomplete, especially for
newly developed drugs. In our previous studies, we
found that well-controlled diabetic patients with in-
sulin and SU showed significantly higher RQ values
compared to normal subjects. Those with RQ
values >1.0 gained more weight after they started
drug treatment. Nateglinide, a rapid insulin secre-
tagogue, facilitates the early phase of insulin se-
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cretion and has been used in the treatment of type
2 diabetic patients with postprandial hyperglyce-
mia. However, the duration of its action is much
shorter than classic SUs. Therefore, a lower RQ
and less fat accumulation would be expected in
subjects being treated with nateglinide.
In the present study, we compared the effect of
nateglinide on RQ and weight gain and the results
were compared with those for a standard SU agent,
glibenclamide.
PATIENTS AND METHODS
1) Patients
The subjects were 20 patients being treated
with nateglinide and 14 patients being treated with
glibenclamide (Table 1). They were diagnosed as
having non-insulin-dependent diabetes mellitus ac-
cording to the criteria established by the Japanese
Society of Diabetes (1999) : a morning fasting plasma
glucose (FPG) level of 126 mg/dl or more, or a
casual plasma glucose level of 200 mg/dl or more.
In the nateglinide group, 90 mg of nateglinide was
administered before each meal for a period of 6
months, and the mean HbA1c level was 6.7 ±0.78 %
(mean±SD). In the glibenclamide group, 2.5 mg
of glibenclamide was administered before break-
fast for a period of 6 months, and the mean HbA1c
level was 7.0±0.64 %. Furthermore, there were no
major diabetic complications in either group. There
were no significant differences in gender, age, body
mass index (BMI), or FPG between the two groups.
As complications, hypertension and hyperlipidemia
were observed in 12 and 10 patients in the nateg-
linide group and in 8 and 6 patients in the gliben-
clamide group, respectively, without significant dif-
ferences between the two groups (the subjects
with hypertension and smokers were excluded in
the present study).
The present study was approved by the direc-
tors of the medical office, and informed consent was
given to the patients or their family after full expla-
nation of the purpose of this study.
2) Measurement of plasma glucose and RQ (Fig.1)
The protocol of this study is outlined in Fig. 1.
The RQ was measured for 10 minutes using a TEEM-
100 device (Aero Sport Inc. Ann Arbor Michigan,
USA) or an AE-300S device (MINATO Inc. Osaka,
Japan). The subjects were rested in a sitting position
10 minutes prior to the examination until the end
of the examination, and the nose and mouth was
covered with a mask. After confirming the absence
of leakage in the measurement circuit, the RQ was
measured only on spontaneous respiration. To elimi-
nate measurement errors related to residual air in
the circuit immediately after the start of the exami-
nation and the influence of hyperventilation, themean
over the latter 5 minutes was taken as the RQ value.
After administering nateglinide at 90 mg or gliben-
clamide at 2.5 mg, a Trelan-G (75 g glucose) tolerance
test was performed. The plasma glucose level and
RQ were measured before loading and at 30, 60,
90, 150, and 180 minutes after loading. To avoid
the influence of motion, the subjects were rested
in a sitting position before and after measurement.
3) Ratio of immunoreactive insulin change to plasma
glucose change (∆IRI /∆PG) and homeostasis model
assessment-insulin resistance (HOMA-IR)
When the plasma glucose level and RQ were
measured, ∆IRI/∆PG was calculated by dividing
IRI 30 minutes after the ingestion of Trelan-G by
plasma glucose changes after 30 minutes to inves-
tigate insulin secretion. Furthermore, we compared
insulin resistance between the two groups by
HOMA-IR measurements.
4) Measurement of body weight
In the two groups, the daily calorie intake was
Table 1 Patient characteristics
Nateglinide (n=20) Glibenclamide (n=14) p value
Sex(men/women)
Age (years)
Body height (cm)
Body weight (kg)
BMI (kg/m2)
FPG (mg/dl)
9/11
67.7±8.5
156.8±9.4
57.1±10.6
23.4±4.9
135.1±21.2
6/8
70.4±8.9
154.1±12.1
61.3±6.8
25.8±2.8
132.4±40.0
ns
ns
ns
ns
ns
ns
BMI, body mass index ; FPG, fast plasma glucose. (mean±SD)
Fig. 1. Protocol for this study.
RQ, respiratory quotient.
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established as the standard body weight×25 kcal/
day for diet therapy. The mean body weight was
measured 6, 3, and 1 month before the examination
and on the day of examination to compare changes
in body weight.
RESULTS
1) Case presentation in the nateglinide and gliben-
clamide groups
The plasma glucose levels and RQ for a 62-year-
old female (HbA1c : 6.4%) in the nateglinide group
are shown in Fig. 2. The FPG levels were 101 mg/dl,
and 180 mg/dl after 2 hours. The RQ values before
75 g OGTT loading and 60, 120, and 180 minutes
after loading were 0.791, 0.834, 0.861, and 0.804,
respectively, similar to the RQ pattern in healthy
adults.
The plasma glucose levels and RQ in a 65-year-
old male (HbA1c : 6.7%) in the glibenclamide group
are shown in Fig. 3. FPG levels were 102 mg/dl,
and 176 mg/dl after 2 hours. The RQ values before
75 g OGTT loading and 60, 120, and 180 minutes
after loading were 0.906, 0.944, 0.988, and 0.978,
respectively, higher than the values in the repre-
sentative patient in the nateglinide group and in
healthy adults.
2) Changes in plasma glucose in the nateglinide and
glibenclamide groups (Fig. 4)
As shown in Fig. 4, we compared the changes in
plasma glucose levels between the two groups. The
plasma glucose levels 180 minutes after a 75 gOGTT
loading in the glibenclamide group was significantly
higher than that in the nateglinide group. However,
there were no significant differences at any other
time points ; thus glycemic control was similar be-
tween the two groups.
3) Changes in RQ in the nateglinide and gliben-
clamide groups (Fig. 5)
As shown in Fig. 5, we compared the changes in
RQ between the two groups. The RQ values before
and after loading in the nateglinide group were
lower than those in the glibenclamide group ; in
Fig. 3. Plasma glucose levels and RQ in a 65-year-old male
(HbA1c : 6.7%) in the glibenclamide group.
RQ, respiratory quotient ; Pre, before 75 g OGTT loading.
Fig. 2. Plasma glucose levels and RQ in a 62-year-old female
(HbA1c : 6.4%) in the nateglinide group.
RQ, respiratory quotient ; Pre, before 75 g OGTT loading.
Fig. 5. Changes in RQ between the two groups.
RQ, respiratory quotient.
Fig. 4. Changes in plasma glucose levels between the twogroups.
PG, plasma glucose level.
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particular, the values were significantly lower before
loading and 30 and 60 minutes after loading (p<0.05).
4) ∆IRI/∆PG in the nateglinide and glibenclamide
groups (Fig. 6)
As shown in Fig. 6, we compared the ∆IRI/∆PG
ratio between the two groups. The ∆IRI/∆PG values
in the nateglinide and glibenclamide groups were
0.227±0.048 and 0.136±0.031, respectively. In the
nateglinide group, initial insulin secretion was
slightly higher, although there was no significant
difference.
5) HOMA-IR in the nateglinide and glibenclamide
groups (Fig. 7)
As shown in Fig. 7, the HOMA-IR values in the
nateglinide and glibenclamide groups were 2.05±
0.27 and 1.87±0.45, respectively. No marked dif-
ference in insulin resistance was found between
the two groups.
6) Changes in mean body weight in the nateglinide
and glibenclamide groups (Fig. 8)
Fig. 8 shows the changes in mean body weight
for the two groups. In the nateglinide group, the
mean body weight values 6 and 3 months prior to
the examination and at the time of the examina-
tion were 59.3±2.8 kg, 58.8±2.7 kg, and 58.2±2.7
kg, respectively, showing slight weight loss. On
the other hand, in the glibenclamide group, the
values were 59.4±3.2 kg, 59.8±3.2 kg, and 61.3±
3.1 kg, respectively, showing weight gain. There was
a significant difference in the influence of the
agent on body weight changes between the two
groups (p=0.0004)
DISCUSSION
Various metabolic disorders involving glucose and
lipid metabolism occur in subjects with diabetes
mellitus. The levels of plasma glucose and HbA1c,
which are routinely used in the assessment of dia-
betes, are useful for evaluating only plasma glu-
cose, that is, a portion of the metabolic state in dia-
betes. However, RQ is a noninvasive and simple
test for evaluating not only glucose metabolism
but lipid metabolism as well. The RQ value is cal-
culated by dividing carbon dioxide output by oxygen
intake. Thus, when glucose alone is utilized as an
energy source, the value is 1.0. When lipids alone are
Fig. 7. HOMA-IR values in the nateglinide and glibenclamide
groups.
HOMA-IR, homeostasis model assessment-insulin resistance.
Fig. 8. Changes in meanbodyweight in the nateglinide and gliben-
clamide groups.
BW, body weight ; M, month.
Fig. 6. Comparison of ∆IRI/∆PG between the two groups.
∆IRI /∆PG, ratio of immunoreactive insulin change to plasma
glucose change.
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utilized, the value is 0.7. Therefore, this parameter
reflects the ratio of glucose metabolism and lipid
metabolism (5).
In a prospective UKPDS study involving patients
with type II diabetes in England (6), obesity was
frequent despite an increase in the incidence of
hypoglycemia in the intensified therapy group in
which stricter glycemic control was required. Yki-
Jarvinen et al. indicated that routine treatment with
SU agents may promote obesity (7). Carlson et al .
also reported that intensified insulin therapy de-
creased the incidence of complications, but led to
weight gain (8). Weight gain is mainly associated
with an increase in fat, indicating that this finding
causes further insulin resistance, disorders in lipid
metabolism, and hypertension.
There are several studies of the relations between
nateglinide and obesity (9-11). Ravussin et al . (12)
and Nakaya et al . (13) reported that weight gain
was frequent in patients with a high RQ value, sug-
gesting that the RQ can be useful for predicting
subsequent body weight changes.
In the present study, changes in the plasma glu-
cose levels and ∆IRI/∆PG and HOMA-IR values
showed that glycemic control, balanced by insulin
secretion and resistance, was similar between the
nateglinide and glibenclamide groups. The differ-
ence in RQ in the present study may have been
related to the difference in fat combustion or syn-
thesis. When fat is metabolized, the RQ value de-
creases to approximately 0.7. In contrast, for fat
synthesis, 1 mol of triglyceride is synthesized from
glucose, and 23 mol of oxygen are produced. Thus,
oxygen ingested via respiration is conserved, and
the RQ increases to approximately 1 or greater. In
some patients with diabetes being treated with in-
sulin or SU, the RQ value exceeds 1 (13).
In the present study, in the nateglinide group,
the RQ values before loading as well as 30 and 180
minutes after loading were significantly lower than
those in the glibenclamide group, suggesting that
the ratio of fat combustion was high in the nateg-
linide group, and that the ratio of fat synthesis was
high in the glibenclamide group. High RQ values
before glucose loading indicate that, even during
the interdigestion period such as early morning or
before meals, fat is still synthesized in these pa-
tients. This is consistent with the changes in body
weight during the 6 months period before the ex-
amination, that is, weight loss in the nateglinide
group and weight gain in the glibenclamide group.
The interval for the blood concentration of
glibenclamide to reached a maximum (Tmax) is 3
to 4 hours (14). However, for nateglinide, it is 30
minutes demonstrating that the latter would have a
more immediate action (15). Therefore, nateglinide
may not cause a rapid increase in plasma glucose,
and may inhibit the elevation of postprandial plasma
glucose levels, with a total insulin secretion than
that in the glibenclamide group (16). In addition,
nateglinide immediately dissociates from the sul-
fonylurea receptors of pancreatic βcells (17), and
the action time of nateglinide is within 3 hour (18),
shortening the duration of a high-insulin state,
whereas the action time of glibenclamide is about
12 hours (19). Insulin promotes fat synthesis from
glucose. Therefore, treatment with nateglinide may
reduce the risk of hypoglycemia as well as weight
gain.
Consistent with our results, Fukuda et al . (20)
reported that nateglinide therapy for 6 months de-
creased plasma glucose levels without increasing
BMI. In Americans, Horton et al. (21) reported that
there were no significant changes in body weight
(less than 1 kg) after single therapy with nateg-
linide for 6 months. Alternately, the difference in
the actions on KATP channels in the hypothalamus
between nateglinide and glibenclamide may play a
role in the less frequent weight gain related to
nateglinide (22, 23).
There was no significant difference in HOMA-IR
in both groups, but insulin secretion and resis-
tance in response to a glucose stimulus was de-
creased in glibenclamide group because the
plasma glucose levels 180 minutes after 75 g OGTT
were significantly higher than the nateglinide group
in the present study,. Therefore, we cannot deny
that hyperglycemia after a food intake due to the
severity of diabetes progression cause obesity be-
sides pharmaceutical influence of diabetic drugs.
CONCLUSION
RQ values in the nateglinide group was lower than
those in the glibenclamide group. The RQ is useful
for predicting weight gain. Nateglinide may not pro-
mote fat synthesis, and may not cause obesity. In
the glibenclamide group, the RQ values after fasting
as well as 30 and 180 minutes after loading were
higher, suggesting that glibenclamide promotes fat
synthesis immediately and for a period of 3 hours
after an oral administration.
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